See more : Antengene Corporation Limited (6996.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Avantor, Inc. (AVTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avantor, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Garibaldi Resources Corp. (GGIFF) Income Statement Analysis – Financial Results
- CF Acquisition Corp. VI (CFVIU) Income Statement Analysis – Financial Results
- Dongwon F&B Co., Ltd. (049770.KS) Income Statement Analysis – Financial Results
- Grid Battery Metals Inc. (EVKRF) Income Statement Analysis – Financial Results
- Moon Equity Holdings Corp. (MONI) Income Statement Analysis – Financial Results
Avantor, Inc. (AVTR)
About Avantor, Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.97B | 7.51B | 7.39B | 6.39B | 6.04B | 5.86B | 1.25B | 691.30M | 636.90M | 4.91B |
| Cost of Revenue | 4.60B | 4.91B | 4.88B | 4.31B | 4.12B | 4.04B | 814.60M | 371.60M | 374.70M | 2.31B |
| Gross Profit | 2.36B | 2.60B | 2.50B | 2.08B | 1.92B | 1.82B | 432.80M | 319.70M | 262.20M | 2.60B |
| Gross Profit Ratio | 33.93% | 34.65% | 33.88% | 32.54% | 31.80% | 31.03% | 34.70% | 46.25% | 41.17% | 53.01% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.10M | 21.90M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.51B | 1.47B | 1.53B | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 201.60M | 1.47B |
| Other Expenses | 0.00 | -800.00K | 10.60M | 9.90M | 2.50M | 3.00M | 3.40M | 200.00K | -300.00K | 0.00 |
| Operating Expenses | 1.66B | 1.47B | 1.53B | 1.37B | 1.37B | 1.41B | 643.20M | 309.80M | 201.90M | 1.47B |
| Cost & Expenses | 6.26B | 6.38B | 6.41B | 5.69B | 5.49B | 5.45B | 1.46B | 681.40M | 576.60M | 3.78B |
| Interest Income | 0.00 | 265.80M | 229.30M | 307.60M | 440.00M | 0.00 | 0.00 | 0.00 | 30.60M | 0.00 |
| Interest Expense | 284.80M | 265.80M | 217.40M | 307.60M | 440.00M | 523.80M | 200.90M | 80.30M | 0.00 | -265.80M |
| Depreciation & Amortization | 402.30M | 405.50M | 379.20M | 395.40M | 398.90M | 404.60M | 99.20M | 60.30M | 60.70M | 0.00 |
| EBITDA | 1.13B | 1.53B | 1.35B | 765.30M | 879.50M | 814.60M | -91.20M | 70.40M | 121.10M | 1.13B |
| EBITDA Ratio | 16.19% | 20.43% | 18.44% | 17.39% | 15.78% | 14.00% | -8.64% | 10.18% | 19.00% | 23.02% |
| Operating Income | 696.40M | 1.13B | 972.20M | 706.80M | 551.80M | 413.50M | -210.40M | 9.90M | 60.30M | 1.13B |
| Operating Income Ratio | 10.00% | 15.04% | 13.16% | 11.05% | 9.14% | 7.05% | -16.87% | 1.43% | 9.47% | 23.02% |
| Total Other Income/Expenses | -285.90M | -279.10M | -219.20M | -644.50M | -511.20M | -527.30M | -249.80M | -80.50M | -30.50M | -279.10M |
| Income Before Tax | 410.50M | 851.10M | 753.00M | 62.30M | 40.60M | -113.80M | -460.20M | -70.60M | 29.80M | 851.10M |
| Income Before Tax Ratio | 5.89% | 11.33% | 10.19% | 0.97% | 0.67% | -1.94% | -36.89% | -10.21% | 4.68% | 17.34% |
| Income Tax Expense | 89.40M | 164.60M | 180.40M | -54.30M | 2.80M | -26.90M | -314.90M | 10.10M | 17.10M | -164.60M |
| Net Income | 321.10M | 686.50M | 572.60M | 116.60M | 37.80M | -86.90M | -112.70M | -42.40M | 21.60M | 686.50M |
| Net Income Ratio | 4.61% | 9.14% | 7.75% | 1.82% | 0.63% | -1.48% | -9.03% | -6.13% | 3.39% | 13.98% |
| EPS | 0.48 | 1.02 | 0.86 | 0.20 | -0.84 | -0.18 | -0.23 | -0.09 | 0.04 | 1.05 |
| EPS Diluted | 0.47 | 1.01 | 0.85 | 0.20 | -0.84 | -0.18 | -0.23 | -0.09 | 0.04 | 1.01 |
| Weighted Avg Shares Out | 675.60M | 650.90M | 590.50M | 576.30M | 401.20M | 496.50M | 496.50M | 491.30M | 534.29M | 650.90M |
| Weighted Avg Shares Out (Dil) | 678.40M | 679.40M | 599.60M | 583.40M | 401.20M | 496.50M | 496.50M | 491.30M | 534.29M | 679.40M |
Broyhill's Q2 2024 Top Five Investments
Avantor® Achieves Bronze Medal from EcoVadis for Sustainability Performance
Avantor® to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt
Avantor® Enters into Definitive Agreement to Divest Clinical Services Business to Audax Private Equity
Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines
Avantor Analysts Increase Their Forecasts After Better-Than-Expected Earnings
Avantor, Inc. (AVTR) Q2 Earnings and Revenues Beat Estimates
Avantor® Reports Second Quarter 2024 Results
Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600
Source: https://incomestatements.info
Category: Stock Reports